title: [Phase II clinical trial of docetaxel, platinum and S-1 for advanced gastric cancer].
abstract: OBJECTIVE
  To evaluate the efficacy and safety profile and to explore the role of docetaxel, S-1 plus cisplatin (DCS) or oxaliplatin (DOS) in the treatment of advanced gastric cancer.
  
  
  METHODS
  A total of 45 patients with advanced gastric cancer were recruited. They received DCS or DOS at the discretion of investigators. Docetaxel was given intravenously at the dose of 60 mg/m² at d1, S-1 60 mg×m⁻²×d⁻¹ or 80 - 120 mg/d according to individual patient's area of body surface orally from d1 to d14 and cisplatin 30 mg/m² at d1, d2 or oxaliplatin 111 - 127 (median: 117) mg/m ²at d2. Each cycle was for 21 days.
  
  
  RESULTS
  Forty-three patients received ≥ 1 complete cycle of DCS/DOS with a median cycle number of 5(range: 1 - 8). Among 42 patients evaluated for efficacy, the outcomes were partial response (n = 28), stable disease (n = 9) and progression (n = 5). The response rate was 66.7%. Progression-free survival (PFS) of 32 patients on chemotherapy alone was 7.1 months and the median overall survival (OS) was not reached. The most common grade 3/4 adverse effects included neutropenia (46.5%), thrombocytopenia (9.3%), vomiting (9.3%), nausea (7.0%) and diarrhea (4.7%). Ten of fourteen patients with advanced unresectable gastric cancer without clinically detectable distant metastases underwent surgical resection after a median of 4 (2-6) cycles of DCS or DOS and 9 (64.3%) had R0 resection.
  
  
  CONCLUSIONS
  DCS/DOS is effective for advanced gastric cancer and in the setting of neoadjuvant chemotherapy. And the toxicities of DCS/DOS are manageable.
authors.affiliation: Cancer Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Ai-ping
authors.initials: AP
authors.lastname: Zhou
authors.forename: Yu-sheng
authors.initials: YS
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.forename: Yan
authors.initials: Y
authors.lastname: Song
authors.forename: Yong-kun
authors.initials: YK
authors.lastname: Sun
authors.forename: Wen
authors.initials: W
authors.lastname: Zhang
authors.forename: Cheng-xu
authors.initials: CX
authors.lastname: Cui
authors.forename: Yihebali
authors.initials: Y
authors.lastname: Chi
authors.forename: Xing-hua
authors.initials: XH
authors.lastname: Yuan
authors.forename: Ning
authors.initials: N
authors.lastname: Lü
authors.forename: Jin-wan
authors.initials: JW
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D010984:Platinum / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010984:Platinum; D010094:Oxonic Acid